FR11C0053I2 - Molecules ctla4 mutantes solubles et leurs utilisations - Google Patents

Molecules ctla4 mutantes solubles et leurs utilisations

Info

Publication number
FR11C0053I2
FR11C0053I2 FR11C0053C FR11C0053C FR11C0053I2 FR 11C0053 I2 FR11C0053 I2 FR 11C0053I2 FR 11C0053 C FR11C0053 C FR 11C0053C FR 11C0053 C FR11C0053 C FR 11C0053C FR 11C0053 I2 FR11C0053 I2 FR 11C0053I2
Authority
FR
France
Prior art keywords
ctla4 molecules
soluble mutant
mutant ctla4
soluble
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR11C0053C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of FR11C0053I1 publication Critical patent/FR11C0053I1/fr
Application granted granted Critical
Publication of FR11C0053I2 publication Critical patent/FR11C0053I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR11C0053C 2000-05-26 2011-12-07 Molecules ctla4 mutantes solubles et leurs utilisations Active FR11C0053I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57992700A 2000-05-26 2000-05-26
US21406500P 2000-06-26 2000-06-26
PCT/US2001/017139 WO2001092337A2 (en) 2000-05-26 2001-05-23 Soluble ctla4 mutant molecules and uses thereof

Publications (2)

Publication Number Publication Date
FR11C0053I1 FR11C0053I1 (de) 2012-01-13
FR11C0053I2 true FR11C0053I2 (fr) 2013-01-11

Family

ID=26908652

Family Applications (1)

Application Number Title Priority Date Filing Date
FR11C0053C Active FR11C0053I2 (fr) 2000-05-26 2011-12-07 Molecules ctla4 mutantes solubles et leurs utilisations

Country Status (41)

Country Link
EP (3) EP1536234B1 (de)
JP (1) JP4328525B2 (de)
KR (2) KR100895134B1 (de)
CN (2) CN101255192A (de)
AR (1) AR031699A1 (de)
AT (1) ATE271066T1 (de)
AU (2) AU6346601A (de)
BE (1) BE2011C041I2 (de)
BR (1) BRPI0111191B8 (de)
CA (1) CA2409748C (de)
CY (2) CY2011019I2 (de)
CZ (1) CZ304451B6 (de)
DE (2) DE60104282T2 (de)
DK (1) DK1248802T3 (de)
EC (1) ECSP024365A (de)
EE (2) EE05458B1 (de)
EG (1) EG24459A (de)
ES (2) ES2571852T3 (de)
FR (1) FR11C0053I2 (de)
GE (1) GEP20053658B (de)
HK (2) HK1048126B (de)
HU (2) HU228137B1 (de)
IL (1) IL152315A (de)
LT (1) LT5133B (de)
LU (1) LU91902I2 (de)
LV (1) LV12994B (de)
MX (1) MXPA02011534A (de)
MY (1) MY136113A (de)
NO (2) NO330797B1 (de)
PE (1) PE20011338A1 (de)
PL (1) PL206267B1 (de)
PT (1) PT1248802E (de)
RU (1) RU2283847C2 (de)
SI (1) SI1248802T1 (de)
SK (1) SK288131B6 (de)
TR (1) TR200402703T4 (de)
TW (2) TWI319405B (de)
UA (1) UA87432C2 (de)
UY (1) UY26723A1 (de)
WO (1) WO2001092337A2 (de)
ZA (1) ZA200208944B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
PT1372696E (pt) 2000-07-03 2008-10-24 Bristol Myers Squibb Co Métodos para o tratamento de doenças reumáticas utilizando uma molécula ctla4 solúvel
WO2002094202A2 (en) 2001-05-23 2002-11-28 Bristol-Myers Squibb Company Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules
WO2003088991A1 (en) * 2002-04-19 2003-10-30 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
DE10232697A1 (de) * 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
US7332303B2 (en) * 2002-12-23 2008-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
BR0317723A (pt) * 2002-12-23 2005-11-22 Bristol Myers Squibb Co Processo de cultura de células de mamìfero para a produção de proteìna
JP2006517191A (ja) 2002-12-30 2006-07-20 アムジエン・インコーポレーテツド 共刺激因子を用いた併用療法
WO2005044188A2 (en) 2003-10-27 2005-05-19 Amgen Inc. Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
KR101398713B1 (ko) * 2005-12-20 2014-06-12 브리스톨-마이어스 스큅 컴퍼니 조성물 및 조성물의 제조 방법
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
US7510844B2 (en) 2006-01-24 2009-03-31 Bristol-Myers Squibb Company CD86 and CD80 receptor competition assays
WO2008005290A2 (en) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
GB0620934D0 (en) 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
BRPI0720565A2 (pt) 2006-12-20 2013-09-17 Mmr Information Systems Inc anticorpos e mÉtodos para a sua preparaÇço e seu uso
DK2222697T3 (da) 2007-11-01 2013-03-11 Perseid Therapeutics Llc Immunsuppressive polypeptider og nukleinsyrer
PT2344540T (pt) * 2008-10-02 2018-02-02 Aptevo Res & Development Llc Proteínas de ligação multi-alvo antagonistas de cd86
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
KR20130049775A (ko) * 2010-03-12 2013-05-14 애브비 바이오테라퓨틱스 인크. Ｃｔｌａ４ 단백질 및 이의 용도
CN103534345A (zh) 2011-02-23 2014-01-22 安姆根有限公司 用于uvc暴射的细胞培养基及其相关方法
WO2013010537A1 (en) 2011-07-20 2013-01-24 Aarhus Universitet Method of treating morphea
WO2013148049A1 (en) * 2012-03-29 2013-10-03 The General Hospital Corporation Recombinant cytotoxic t-lymphocyte-associated protein 4 (ctla4)
BR112014026718B1 (pt) 2012-05-11 2021-05-18 Medimmune Limited. polipeptídeo isolado de ctla-4, célula hospedeira, composição e uso de um polipeptídeo ctla-4
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
CA2877986A1 (en) 2012-06-27 2014-01-03 Orban Biotech Llc Ctla4 fusion proteins for the treatment of diabetes
US20140112958A1 (en) 2012-10-24 2014-04-24 Mwm Biomodels Gmbh Pancreatic islets of transgenic LEA29Y animals for treating diabetes
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
SG10201806643WA (en) 2014-01-13 2018-09-27 Amgen Inc Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
EP3521440B1 (de) 2014-06-04 2022-02-09 Amgen Inc. Verfahren zur gewinnung von säugetierzellkulturen
EP3680344A1 (de) 2014-12-01 2020-07-15 Amgen Inc. Verfahren zur manipulation des glycangehalts eines glycoproteins
US10590457B2 (en) 2015-02-11 2020-03-17 Bristol Myers-Squibb Company Compositions for cell culture and methods of using the same
DK3283508T3 (en) 2015-04-17 2021-05-31 Alpine Immune Sciences Inc Immunomodulatory Proteins with Tunable Affinities
EP3702470A3 (de) 2015-09-09 2020-10-07 The Trustees of Columbia University in the City of New York Reduktion von er-mam-lokalisiertem app-c99 und verfahren zur behandlung von morbus alzheimer
US11401509B2 (en) 2015-11-09 2022-08-02 Bristol-Myers Squibb Company Methods of minimizing glycoprotein agregation in CHO cell production
CA3036997A1 (en) * 2016-09-19 2018-03-22 Oncoimmune, Inc. Cytotoxic t-lymphocyte-associated antigen-4(ctla-4)-fc fusion proteins and use thereof for treating adverse events associated with cancer immunotherapy
CN107987153A (zh) * 2016-10-27 2018-05-04 广东香雪精准医疗技术有限公司 高亲和力的可溶性pd-1分子
CA3077509A1 (en) 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
CN109453383A (zh) * 2018-11-12 2019-03-12 陈慧慧 免疫检查点的抑制剂在制备治疗青光眼及其他眼部免疫损伤机制相关疾病药物中的应用
WO2021038296A2 (en) 2019-08-27 2021-03-04 Tonix Pharma Holdings Limited Modified tff2 polypeptides
TW202128743A (zh) 2019-12-06 2021-08-01 美商再生元醫藥公司 抗ｖｅｇｆ蛋白組合物及其製備方法
JP2023530712A (ja) 2020-06-18 2023-07-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 未処理ｃ末端リジンを正確に測定するための重ペプチドアプローチ
WO2022027013A1 (en) 2020-07-28 2022-02-03 Seagen Inc. Methods and systems for producing polypeptides
WO2023115027A2 (en) 2021-12-16 2023-06-22 Bristol-Myers Squibb Company Detergent for viral inactivation
US20240010737A1 (en) 2022-03-02 2024-01-11 Regeneron Pharmaceuticals, Inc. Manufacturing process for high titer antibody

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
ATE170562T1 (de) * 1991-06-27 1998-09-15 Bristol Myers Squibb Co Ctl4a rezeptor, ihn enthaltenden fusionsproteine und deren verwendungen
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
JP2003532370A (ja) * 1998-10-07 2003-11-05 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 新規なＴｈ２特異的分子およびその使用方法
PT1372696E (pt) * 2000-07-03 2008-10-24 Bristol Myers Squibb Co Métodos para o tratamento de doenças reumáticas utilizando uma molécula ctla4 solúvel

Also Published As

Publication number Publication date
RU2283847C2 (ru) 2006-09-20
KR100889887B1 (ko) 2009-03-24
EE05557B1 (et) 2012-08-15
HK1048126B (zh) 2005-03-04
EE05458B1 (et) 2011-08-15
TW200906857A (en) 2009-02-16
ECSP024365A (es) 2003-03-31
AR031699A1 (es) 2003-10-01
LV12994B (en) 2003-08-20
IL152315A (en) 2010-04-15
EP1248802B9 (de) 2005-05-11
HU228137B1 (en) 2012-12-28
TWI319405B (en) 2010-01-11
BE2011C041I2 (de) 2020-08-20
MXPA02011534A (es) 2004-08-12
CZ20023892A3 (cs) 2003-09-17
ES2571852T3 (es) 2016-05-27
IL152315A0 (en) 2003-05-29
HK1048126A1 (en) 2003-03-21
NO20025656D0 (no) 2002-11-25
ZA200208944B (en) 2004-02-13
KR20030009502A (ko) 2003-01-29
EE200200659A (et) 2004-06-15
DE60104282T2 (de) 2005-10-13
CY1117625T1 (el) 2017-04-26
CA2409748A1 (en) 2001-12-06
CZ304451B6 (cs) 2014-05-14
DK1248802T3 (da) 2004-11-15
DE60104282D1 (de) 2004-08-19
EG24459A (en) 2009-07-16
UA87432C2 (uk) 2009-07-27
SK288131B6 (sk) 2013-10-02
WO2001092337A3 (en) 2002-05-10
HUP0302201A2 (hu) 2003-10-28
EP1536234A2 (de) 2005-06-01
BR0111191A (pt) 2004-07-06
NO2011027I2 (de) 2011-12-15
HUS1300012I1 (hu) 2016-08-29
PL206267B1 (pl) 2010-07-30
FR11C0053I1 (de) 2012-01-13
ATE271066T1 (de) 2004-07-15
MY136113A (en) 2008-08-29
TWI314933B (en) 2009-09-21
JP4328525B2 (ja) 2009-09-09
CY2011019I1 (el) 2016-12-14
EP3029062A1 (de) 2016-06-08
CA2409748C (en) 2008-09-16
CY2011019I2 (el) 2016-12-14
EP1248802A2 (de) 2002-10-16
AU2001263466B2 (en) 2006-04-27
CN101255192A (zh) 2008-09-03
SK15702002A3 (sk) 2004-01-08
UY26723A1 (es) 2001-12-28
BRPI0111191B8 (pt) 2021-05-25
JP2004511213A (ja) 2004-04-15
PT1248802E (pt) 2004-11-30
EP1536234B1 (de) 2016-03-16
GEP20053658B (en) 2005-11-10
HK1071931A1 (zh) 2005-08-05
NO330797B1 (no) 2011-07-18
LT5133B (lt) 2004-05-25
DE122011100063I1 (de) 2012-06-14
HUP0302201A3 (en) 2010-01-28
KR20070094019A (ko) 2007-09-19
LU91902I2 (fr) 2012-01-16
PL366231A1 (en) 2005-01-24
SI1248802T1 (en) 2005-02-28
EP1536234A3 (de) 2009-06-03
BRPI0111191B1 (pt) 2019-12-31
AU2001263466C1 (en) 2006-10-26
NO2011027I1 (no) 2012-01-09
NO20025656L (no) 2002-11-25
WO2001092337A2 (en) 2001-12-06
EP1248802B1 (de) 2004-07-14
TR200402703T4 (tr) 2004-11-22
ES2225549T3 (es) 2005-03-16
LT2002114A (en) 2003-12-29
KR100895134B1 (ko) 2009-05-04
CN1441810A (zh) 2003-09-10
AU6346601A (en) 2001-12-11
PE20011338A1 (es) 2002-01-13
EE201100050A (et) 2011-10-17
CN1309735C (zh) 2007-04-11

Similar Documents

Publication Publication Date Title
FR11C0053I2 (fr) Molecules ctla4 mutantes solubles et leurs utilisations
FR18C0002I2 (fr) Derives bacteriochlorophylles anioniques solubles dans l'eau et leurs utilisations
MA27035A1 (fr) Ligands de recepteurs de 5-ht et leurs utilisations
FR14C0064I2 (fr) Anticorps anti-il-6, compositions, methodes et utilisations associees
DE60009886D1 (de) Polysaccharidfasern
DE50013828D1 (de) Differenzverstärker
AU2001263466A1 (en) Soluble CTLA4 mutant molecules and uses thereof
DK1228217T3 (da) Konserverede neisseria-antigener
BR0100925B1 (pt) conjunto de painéis e elementos de junção.
DK1517001T3 (da) Ekspanderanordning nede i borehullet
FR2819410B1 (fr) Composition cosmetique irisee et ses utilisations
IT1316763B1 (it) Differenziale
DE60045802D1 (de) Differenzverstärkerschaltung
DE10163359B4 (de) Pyridinderivat und dessen Komplex
DE60106372D1 (de) Redox System und Verfahren
DE60109480D1 (de) Panelverbinder
FR2819411B1 (fr) Composition cosmetique irisee et ses utilisations
DE50108630D1 (de) Differentieller, komplementärer verstärker
FR2778317B1 (fr) Composition edulcorante et ses utilisations
ATE289720T1 (de) Transaktionszertifizierung
FR2819412B1 (fr) Composition cosmetique irisee et ses utilisations
FR2800076B1 (fr) Mannoproteines solubles
DE50015931D1 (de) Differentialschutzverfahren
FR2834991B1 (fr) Nouveaux anticorps anti-igf-ir et leurs applications
FR2778822B1 (fr) Composition edulcorante et ses utilisations